Cytokines as potential tumour markers

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 6, 2008, Pages 691-711

  Chechlinska, Magdalena ^a   Kowalska, Maria ^a   Kaminska, Janina ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Cancer; Cytokine; Diagnostic marker; Expression; Prognostic factor; Receptor; Sarcoma; Serum

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BASIC FIBROBLAST GROWTH FACTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; SOMATOMEDIN BINDING PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULOTROPIN; VASCULOTROPIN C;

ADJUVANT THERAPY; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDLINE; OSTEOSARCOMA; OVARY ADENOCARCINOMA; OVARY CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOFT TISSUE SARCOMA; STOMACH CANCER; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 77953470293     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2.6.691     Document Type: Review

References (193)

1. Voorzanger-Rousselot N, Garnero P. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. Cancer Treat Rev 2007;33:230-83
2. Jain KK. Cancer biomarkers: current issues and future directions. Curr Opin Mol Ther 2007;9:563-71
3. Zhang X, Li L, Wei D, et al. Moving cancer diagnostics from bench to bedside. Trends Biotechnol 2007;25:166-73
4. Ibelgauft H. COPE, Online Pathfinder Encyclopedia, Available from: www.copewithcytokines.de/cope.cgi [Last accessed 15 January 2008]
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
6. Chechlinska M. The role of cytokines in carcinogenesis. Nowotwory J Oncol 2003;53:648-59
7. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002;12:113-20
8. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007;121:1-14
9. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol 2002;17:623-37
10. Ahmad SA, Jung YD, Liu W, et al. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol 2002;2:105-12
11. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part I). Active stromal participants in tumor development and progression? Histol Histopathol 2002;17:599-621
12. Sheski ED, Nararajan V, Pottratz ST. Tumor necrosis factor-alpha stimulates attachment of small cell lung carcinoma to endothelial cells. J Lab Clin Med 1999;133:265-73
13. Yabushita H, Shimazu M, Noguchi M, et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep 2003;10:89-95
14. Gaffney DK, Haslam D, Tsodikov A, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:922-8
15. Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 2002;87:84-9
16. Psyrri A, Kassar M, Yu Z, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005;11:8637-43
17. Nishio Y, Yamada Y, Kokubo H, et al. Prognostic significance of immunohistochemical expression of the HER2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006;68:110-5
18. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;13(358):1160-74
19. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Supl 4S):9-15
20. Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007;31:1458-68
21. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6
22. Dobbs SP, Hewett PW, Johnson IR, et al. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer 1997;76:1410-5
23. Kodama J, Seki N, Tokumo K, et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 1999;35:485-9
24. Loncaster JA, Cooper RA, Logue JP, et al. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000;83:620-5
25. Ryu SY, Oka K, Tsujii H, et al. Platelet-derived endothelial cell growth factor as a prognostic factor for radiotherapy outcome in patients with adenocarcinoma of the uterine cervix. Gynecol Oncol 2003;89:414-9
26. Lee IJ, Park KR, Lee KK, et al. Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2002;54:768-79
27. Tjalma W, Weyler J, Weyn B, et al. The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2000;92:251-7
28. Van Trappen PO, Steele D, Lowe DG, et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003;201:544-54
29. Hashimoto I, Kodama J, Seki N, et al. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer 2001;85:93-7
30. Ueda M, Terai Y, Yamashita Y, et al. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer 2002;98:335-43
31. Branca M, Giorgi C, Santini D, et al. Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J Clin Pathol 2006;59:40-7
32. Fuchs I, Vorsteher N, Bühler H, et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 2007;27:959-63
33. Baiocchi G, Kavanagh JJ, Talpaz M, et al. Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer 1991;67:990-6
34. Fujiwaki R, Iida K, Nakayama K, et al. Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecol Oncol 2003;89:77-83
35. Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 2001;82:49-56
36. Srivani R, Nagarajan B. A prognostic insight on in vivo expression of interleukun-6 in uterine cervical cancer. Int J Gynecol Cancer 2003;13:331-9
37. Fujimoto J, Sakaguchi H, Aoki I, et al. The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers. Cancer Res 2000;60:3662-5
38. Fujimoto J, Sakaguchi H, Aoki I. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res 2000;60:2632-5
39. Lebrecht A, Ludwig E, Huber A, et al. Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol Oncol 2002;85:32-5
40. Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 2005;103:724-30
41. Kotowicz B, Kaminska J, Fuksiewicz M, et al. Tumor markers and cytokines in patients with cervical cancer [abstr P-18]. Tumor Biol 2007;28(Suppl 1):S98
42. Suzuki M, Ohwada M, Sato I, et al. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Oncology 1995;52:128-33
43. Mathur SP, Mathur RS, Underwood PB, et al. Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol 2003;91:486-93
44. Miyatake T, Ueda Y, Nakashima R, et al. Down-regulation of insulin-like growth factor binding protein-5 (IGFBP-5): novel marker for cervical carcinogenesis. Int J Cancer 2007;120:2068-77
45. Wu X, Tortolero-Luna G, Zhao H, et al. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res 2003;9:3356-61
46. Sliutz G, Tempfer C, Obermair A, et al. Serum evaluation of basic fibroblast growth factor in cervical cancer patients. Cancer Lett 1995;94:227-31
47. Ung A, Kramer TR, Schiffman M, et al. Soluble interleukin 2 receptor levels and cervical neoplasia: results from a population-based case-control study in Costa Rica. Cancer Epidemiol Biomarkers Prev 1999;8:249-53
48. Malik S, Balkwill F. Epithelial ovarian cancer: a cytokine propelled disease? Br J Cancer 1991;64:617-20
49. Burke F, Relf M, Negus R, et al. A cytokine profile of normal and malignant ovary. Cytokine 1996;8:578-85
50. Gotlieb WH, Abrams JS, Watson JM, et al. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 1992;4:385-90
51. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-87
52. Moradi MM, Carson LF, Weinberg JB, et al. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993;72:2433-40
53. Plante M, Rubin SC, Wong GY, et al. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994;73:1882-8
54. Barton DPJ, Blanchard EB, Michelini-Norris B, et al. High serum and ascitic soluble interlekin-2 receptor alfa levels in advanced epithelial ovarian cancer. Blood 1993;8:424-9
55. Sedlaczek P, Frydecka I, Gabrys M, et al. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 2002;95:1886-93
56. Yamamoto S, Konishi I, Mandai M, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221-7
57. Chechlinska M, Kaminska J, Marskowska J, et al. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. Int J Biol Markers 2007;22:172-80
58. Punnonen R, Teisala K, Kuoppala T, et al. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Cancer 1998;83:788-96
59. Ivarsson K, Runesson E, Sundfeldt K, et al. The chemotactic cytokine interleukin-8-a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol 1998;71:420-3
60. Secord AA, Darcy KM, Hutson A, et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106:221-32
61. Gan Y, Wientjes MG, Au JL. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 2006;23:1324-31
62. Lu L, Karsaros D, Wiley A, et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 2006;12:1208-14
63. Bozkurt N, Yuce K, Basaran M, et al. Correlation of serum and ascitic IL-12 levels with second-look laparotomy results and disease progression in advanced epithelial ovarian cancer patients. Int J Gynecol Cancer 2006;16:83-6
64. Mustea A, Könsgen D, Braicu EI, et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 2006;26:1715-8
65. Chechlinska M, Kaminska J, Kowalska M, et al. The origin of cytokines, soluble cytokine receptors and CA125 in ascitic fluids and sets of ovarian cancer patients [abstract P-68]. Tumor Biol 2003;24(Supl 1):S76
66. Kaminska J, Kowalska M, Rysinska A, et al. Serum cytokines in non-treated ovarian cancer patients. Monduzzi Editore. Int Proc Division 1999;221-23
67. Scholl AS, Bascou CH, Mosseri V, et al. Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br J Cancer 1994;69:342-6
68. Lancaster JM, Sayer RA, Blanchette C, et al. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer 2006;16:1529-35
69. Fujiwaki R, Hata T, Miyazaki K, et al. Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers. Br J Obstet Gynaecol 1997;104:1407-8
70. Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis an d patient survival in ovarian cancer. Anticancer Res 2004;24:1973-9
71. Berek JS, Chung C, Kaldi K, et al. Serum IL-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obst Gynecol 1991;164:1038-42
72. Kaminska J, Kowalska M, Fuksiewicz M, et al. Prognostic value of pretreatment serum CA 125 and cytokine levels in patients with ovarian cancer [abstr.P0239]. Int J Gynecol 2006;16(Supl 3):S668
73. Hefler LA, Zeillinger R, Grimm C, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 2006;103:512-7
74. Zygmunt A, Madry R, Markowska J, et al. Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer. Eur J Gynaecol Oncol 1999;20:298-301
75. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-7
76. Nicoluni A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006;17:325-37
77. Rao VS, Dyer CE, Jameel JK, et al. Potential prognostic and therapeutic roles for cytokines in breast cancer. Oncol Rep 2006;15:179-85
78. Knüpfer H, Preiss R. Significance of interleukun-6 (IL-6) in breast cancer. Breast Cancer Res Treat 2007;102:129-35
79. Ferretti G, Felici A, Papaldo P, et al. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007;19:56-62
80. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6:3282-9
81. Singer CF, Kronsteiner N, Hudelist G, et al. Interleukun 1 system and sex steroid receptor expression in human breast cancer: interleukin 1 alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 2003;9:4877-83
82. Kurtzman SH, Anderson KH, Wang Y, et al. Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. Oncol Rep 1999;6:65-70
83. Desruisseau S, Palmari J, Giusti C, et al. Determination of TGF beta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 2006;30(94):239-46
84. Jin L, Yuan RQ, Fuchs A, et al. Expression of interleukin-1beta in human breast carcinoma. Cancer 1997;80:421-34
85. Skoog L, Humla S, Axelsson M, et al. Estrogen receptor levels and survival of breast cancer patients. A study on patients participating in randomized trials of adjuvant therapy. Acta Oncol 1987;26:95-100
86. Fuksiewicz M, Kaminska J, Kotowicz B, et al. Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients. Clin Chem Lab Med 2006;44:1092-7
87. Freund A, Chauveau C, Brouillet G, et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003;22:256-65
88. Sheen-Chen SM, Chou FF, Hsu W, et al. Lack of prognostic value of insulin-like growth factor-1 in patients with breast cancer: analysis with tissue microarray. Anticancer Res 2007;27:3541-4
89. Bando H, Weich HA, Brokelmann M, et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 2005;92:553-61
90. Buck MB, Fritz P, Dippon J, et al. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 2004;10:491-8
91. Koumoundourou D, Kassimatis T, Zolota V, et al. Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2, N0 tumours. Anticancer Res 2007;27:2613-20
92. Wu Y, Saldana L, Chillar R, et al. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol 2002;20:509-16
93. Pichon MF, Moulin G, Pallud C, et al. Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients. Anticancer Res 2000;20:1189-94
94. Benoy IH, Salgado R, Van Dam P, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157-62
95. Kozlowski L, Zakrzewska I, Tokajuk P, et al. Concentration of interleukun-6 (IL-6), interleuldn-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 2003;48:82-4
96. Günel N, Coskun U, Sancak B, et al. S. Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage. Am J Clin Oncol 2003;26:416-21
97. Byrne GJ, McDowell G, Agarawal R, et al. Serum vascular endothelial growth factor in breast cancer. Anticancer Res 2007;27:3481-7
98. Bachelot T, Ray-Coquard I, Menetrier-Caux C, et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003;88:1721-6
99. Benoy I, Salgado R, Colpaert C, et al. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002;2:311-5
100. Sheen-Chen SM, Chen WJ, Eng HL, et al. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997;43:211-5
101. Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-9
102. Günel N, Co kun U, Sancak B, et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer 2002;95:663-7
103. Sheen-Chen SM, Liu YW, Eng HL, Chou FF. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:715-7
104. Mettler L, Salmassi A, Heyer M, et al. Perioperative levels of interleukin-1 beta and interleukun-6 in women with breast cancer. Clin Exp Obstet Gynecol 2004;31:20-2
105. Nishimura R, Nagao K, Miyayama H, et al. An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology 2000;59:166-73
106. Arduino S, Tessarolo M, Bellino R, et al. Reduced IL-2 level concentration in patients with breast cancer as a possible risk factor for relapse. Eur J Gynaecol Oncol 1996;17:535-7
107. Ivanovic V, Demajo M, Krtolica K, et al. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 2006;371:191-3
108. Bozcuk H, Uslu G, Samur M, et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004;27:58-65
109. Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003;103:642-6
110. Green MM, Hiley CT, Shanks JH, et al. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 2007;67:84-90
111. Peyromaure M, Badoual C, Camparo P, et al. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer. Oncol Rep 2007;18:145-9
112. Gravdal K, Halvorsen OJ, Haukaas SA, et al. Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch 2006;448:68-74
113. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci 2003;100:3410-5
114. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44
115. Truong LD, Kadmon D, McCune BK, et al. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 1993;24:4-9
116. Shariat SF, Menesses-Diaz A, Kim IY, et al. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004;63:1191-7
117. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7
118. Nam RK, Trachtenberg J, Jewett MA, et al. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:1270-3
119. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-4
120. Borugian MJ, Spinelli JJ, Sun Z, et al. Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Prospective Multiethnic Study. Cancer Epidemiol Biomarkers Prev 2008;17:252-4
121. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099
122. Li L, Yu H, Schumacher F, et al. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003;14:721-6
123. Marszalek M, Wachter J, Ponholzer A, et al. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls. Eur Urol 2005;48:34-9
124. Miyata Y, Sakai H, Hayashi T, et al. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 2003;54:125-32
125. Zhigang Z, Jieming L, Su L, et al. Serum insulin-like growth factor I/ free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml. J Surg Oncol 2007;96:54-61
126. Li H, Kantoff PW, Ma J, et al. Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1557-61
127. Jones A, Fujiyama C, Turner K, et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 2000;85:276-80
128. Duque JL, Loughlin KR, Adam RM, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523-7
129. George DJ, Halabi Shepard TF, et al. Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932-6
130. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702-6
131. Meyer GE, Yu E, Siegal JA, et al. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995;76:2304-11
132. Humphrey PA, Halabi S, Picus J, et al. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer 2006;4:269-77
133. Brown DA, Stephan C, Ward RL, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006;12:89-96
134. Yoshimura H, Dhar DK, Nakamoto T, et al. Prognostic significance of tumor necrosis factor receptor in colorectal adenocarcinoma. Anticancer Res 2003;23:85-9
135. Bacman D, Merkel S, Croner R, et al. TGF-beta receptor 2 downregulation in tumour-associated strains worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma a retrospective study. BMC Cancer 2007;7:156
136. Tsamandas AC, Kardamakis D, Ravazoula P, et al. The potential role of TGF beta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival. Strahlenther Onkol 2004;180:201-8
137. Bellone G, Carbone A, Tibaudi D, et al. Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. Eur J Cancer 2001;37:224-33
138. Zlobec I, Vuong T, Hayashi S, et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 2007;96:793-800
139. Kaminska J, Nowacki M, Kowalska M, et al. Clinical significance of serum cytokine measurements inuntreated colorectal cancer patients: soluble necrosis factor receptor type I - an independent prognostic factor. Tumour Biol 2005;26:186-94
140. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukun-8 in hematogenous metastasis. J Gastroenterol 1994;29:423-9
141. Belluco C, Nitti D, Frantz M, et al. Interleukin-6 blood level is associated with circulating carconoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 2000;7:133-8
142. Davies MM, Jonas SK, Kaur S, et al. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume. Br J Cancer 2000;82:1004-8
143. Nikiteas NI, Tzanakis N, Gazouli M, et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005;11:1639-43
144. Chung YC, Chang YF. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 2003;50:1910-3
145. O'Hara RJ, Grenman J, MacDonalad AW, et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 1998;4:1943-8
146. Ito H, Miki C. Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients. Scand J Gastroenterol 1999;34:1139-43
147. Murakami S, Satomi A, Ishida K, et al. Serum soluble interleukin-2 receptor in colorectal cancer. Acta Oncol 1994;33:19-21
148. Aderka D, Engelmann H, Hornik V, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991;51:5602-7
149. Berghella AM, Pellegrini P, Del Beato T, et al. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer. Cancer Biother Radiopharm 1997;12:265-72
150. Berghella AM, Contasta I, Pellegrini P, et al. Peripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancer. Cancer Biother Radiopharm 2002;17:43-50
151. Pellegrini P, Berghella AM, Contasta I, et al. The study of a patient's immune system may prove to be a useful noninvasive tool for stage classification in colon cancer. Cancer Biother Radiopharm 2006;21:443-67
152. Werther K, Christensen IJ, Nielsen HJ, et al. Colorectal Cancer Study Group: Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Brit J Cancer 2002;86:417-23
153. Yasui W, Oue N, Aung PP, et al. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005;8:86-94
154. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-63
155. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002;236:37-42
156. Saito H, Osaki T, Murakami D, et al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007;95:123-8
157. Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999;5:1823-9
158. Jüttner S, Wissmann C, Jöns T, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006;24:228-40
159. Park DI, Yun JW, Park JH, et al. HER2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-9
160. Wu CW, Wang SR, Chao MF, et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996;91:1417-22
161. Ashizawa T, Okada R, Suzuki Y, et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005;8:124-31
162. Galizia G, Lieto E, De Vita F, et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res 2002;22:473-82
163. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, et al. Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol 2006;12:4473-7
164. Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology 2001;48:1199-201
165. Saito H, Tsujitani S, Ikeguchi M, et al. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer. Oncology 1999;56:253-38
166. Carpagnano GE, Spanevello A, Curci C, et al. IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients. Oncol Res 2007;16:375-81
167. Huang M, Wang J, Lee P, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995;55:3847-53
168. Yuan A, Yang PC, Yu CJ, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 2000;162:1957-63
169. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 2000;89:475-83
170. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001;19:432-41
171. Soria JC, Moon C, Kemp BL, et al. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2003;9:1758-91
172. De Vita F, Orditura M, Auriemma A, et al. Serum concentrations of proinflammatory cytokines in advanced non-small cell lung cancer patients. J Exp Clin Cancer Res 1998;17:413-7
173. Tas F, Duranyildiz D, Argon A, et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 2005;22:353-8
174. Orditura M, Romano C, De Vita F, et al. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother 2000;49:530-6
175. De Vita F, Orditura M, Auriemma A, et al. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998;5:649-52
176. Orditura M, De Vita F, Catalano G, et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 2002;22:1129-35
177. De Vita F, Orditura M, Galizia G, et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000;117:365-73
178. Tisi E, Lissoni P, Angeli M, et al. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer 1992;69:2458-62
179. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005;23:193-200
180. Kaminska J, Kowalska M, Kotowicz B, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. Oncology 2006;70:115-25
181. Yamaguchi T, Yamamoto Y, Yokota S, et al. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol 1998;28:740-4
182. Katsumata N, Eguchi K, Fukuda M, et al. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 1996;2:553-9
183. Brattstrom D, Bergqviest M, Hesselius P, et al. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2004;44:55-62
184. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and INF-?), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11:80-6
185. Laack E, Kohler A, Kugler C, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small cell lung cancer. Ann Oncol 2002;13:1550-7
186. DuBois S, Demetri G. Markers of Angiogenesis and Clinical Features in Patients With Sarcoma. Cancer 2007;109:813-9
187. Rutkowski P, Kaminska J, Kowalska M, et al. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer 2002;100:463-71
188. Kersting C, Packeisen J, Leidinger B, et al. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol 2006;59:585-90
189. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-8
190. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004;10:1344-53
191. Rutkowski P, Kaminska J, Kowalska M, et al. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003;84:151-9
192. Graeven U, Andre N, Achilles E, et al. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 1999;125:577-81
193. Holzer G, Pfandlsteiner T, Blahovec H, et al. Serum levels of TNF-beta and sTNF-R in patients with malignant bone tumours. Anticancer Res 2003;23:3057-9